ERAP1, ERAP2, and Two Copies of HLA-Aw19 Alleles Increase the Risk for Birdshot Chorioretinopathy in HLA-A29 Carriers.
Alleles
Aminopeptidases
/ genetics
Birdshot Chorioretinopathy
/ diagnosis
Gene Frequency
Genetic Predisposition to Disease
Genome-Wide Association Study
Genotyping Techniques
HLA-A Antigens
/ genetics
Haplotypes
Heterozygote
Humans
Minor Histocompatibility Antigens
/ genetics
Multiplex Polymerase Chain Reaction
Odds Ratio
Polymorphism, Single Nucleotide
Risk Factors
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
entrez:
2
11
2021
pubmed:
3
11
2021
medline:
23
11
2021
Statut:
ppublish
Résumé
Birdshot chorioretinopathy (BSCR) is strongly associated with HLA-A29. This study was designed to elucidate the genetic modifiers of BSCR in HLA-A29 carriers. We sequenced the largest BSCR cohort to date, including 286 cases and 108 HLA-A29-positive controls to determine genome-wide common and rare variant associations. We further typed the HLA alleles of cases and 45,386 HLA-A29 controls of European ancestry to identify HLA alleles that associate with BSCR risk. Carrying a second allele that belongs to the HLA-Aw19 broad antigen family (including HLA-A29, -A30, -A31, and -A33) increases the risk for BSCR (odds ratio [OR] = 4.44; P = 2.2e-03). This result was validated by comparing allele frequencies to large HLA-A29-controlled cohorts (n = 45,386; OR > 2.5; P < 1.3e-06). We also confirm that ERAP1 and ERAP2 haplotypes modulate disease risk. A meta-analysis with an independent dataset confirmed that ERAP1 and ERAP2 haplotypes modulate the risk for disease at a genome-wide significant level: ERAP1-rs27432 (OR = 2.46; 95% confidence interval [CI], 1.85-3.26; P = 4.07e-10), an expression quantitative trait locus (eQTL) decreasing ERAP1 expression; and ERAP2-rs10044354 (OR = 1.95; 95% CI, 1.55-2.44; P = 6.2e-09), an eQTL increasing ERAP2 expression. Furthermore, ERAP2-rs2248374 that disrupts ERAP2 expression is protective (OR = 0.56; 95% CI, 0.45-0.70; P = 2.39e-07). BSCR risk is additively increased when combining ERAP1/ERAP2 risk genotypes with two copies of HLA-Aw19 alleles (OR = 13.53; 95% CI, 3.79-54.77; P = 1.17e-05). The genetic factors increasing BSCR risk demonstrate a pattern of increased processing, as well as increased presentation of ERAP2-specific peptides. This suggests a mechanism in which exceeding a peptide presentation threshold activates the immune response in choroids of A29 carriers.
Identifiants
pubmed: 34727153
pii: 2778043
doi: 10.1167/iovs.62.14.3
pmc: PMC8572510
doi:
Substances chimiques
HLA-A Antigens
0
HLA-A19 antigen
0
HLA-A29 antigen
0
Minor Histocompatibility Antigens
0
Aminopeptidases
EC 3.4.11.-
ERAP1 protein, human
EC 3.4.11.-
ERAP2 protein, human
EC 3.4.11.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3Références
Hum Mol Genet. 2018 Dec 15;27(24):4333-4343
pubmed: 30215709
Hum Immunol. 2018 Feb;79(2):109-116
pubmed: 29183862
Curr Opin Ophthalmol. 2014 Nov;25(6):488-94
pubmed: 25211040
Am J Ophthalmol. 1982 Aug;94(2):147-58
pubmed: 6956239
Nat Biotechnol. 2020 Feb;38(2):199-209
pubmed: 31844290
Ocul Immunol Inflamm. 2011 Dec;19(6):397-400
pubmed: 22106906
PLoS Genet. 2009 Dec;5(12):e1000766
pubmed: 20011102
Arthritis Rheumatol. 2015 Nov;67(11):2957-65
pubmed: 26238044
Mol Cell Proteomics. 2018 Aug;17(8):1564-1577
pubmed: 29769354
Nature. 2020 Oct;586(7831):749-756
pubmed: 33087929
Blood. 2008 Aug 1;112(3):708-10
pubmed: 18502829
Nat Genet. 2010 Jun;42(6):508-14
pubmed: 20453842
Sci Rep. 2018 Jul 10;8(1):10398
pubmed: 29991817
Hum Mol Genet. 2014 Nov 15;23(22):6081-7
pubmed: 24957906
Nat Genet. 2011 Jul 10;43(8):761-7
pubmed: 21743469
Genes Immun. 2008 Apr;9(3):249-58
pubmed: 18340360
Orphanet J Rare Dis. 2016 May 12;11(1):61
pubmed: 27175923
Nat Genet. 2016 Oct;48(10):1284-1287
pubmed: 27571263
BMC Bioinformatics. 2014 Jan 29;15:30
pubmed: 24475911
Clin Ophthalmol. 2014;8:73-81
pubmed: 24379650
Am J Ophthalmol. 1980 Jan;89(1):31-45
pubmed: 7356785
Ann N Y Acad Sci. 2006 Oct;1079:1-8
pubmed: 17130525
Hum Immunol. 2019 May;80(5):325-334
pubmed: 30797823
Mol Cell Proteomics. 2018 Jul;17(7):1308-1323
pubmed: 29632046
Nat Genet. 2018 Sep;50(9):1335-1341
pubmed: 30104761
Nat Genet. 2008 Aug;40(8):955-62
pubmed: 18587394
J Biol Chem. 2017 Jun 9;292(23):9680-9689
pubmed: 28446606
Mol Cell Proteomics. 2015 Jul;14(7):1770-80
pubmed: 25892735
Nat Genet. 2010 Nov;42(11):985-90
pubmed: 20953190
Hum Immunol. 2016 Mar;77(3):233-237
pubmed: 26826444
Genes Immun. 1999 Nov;1(2):120-9
pubmed: 11196658
PLoS One. 2013 Jun 06;8(6):e64683
pubmed: 23762245
Am J Ophthalmol. 2006 Jan;141(1):185-7
pubmed: 16386995
Nat Genet. 2021 Jul;53(7):1097-1103
pubmed: 34017140
Clin Rheumatol. 2017 Oct;36(10):2261-2266
pubmed: 28801811
Br J Ophthalmol. 2017 Jul;101(7):851-855
pubmed: 28314830
BMC Genomics. 2014 May 01;15:325
pubmed: 24884790
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
PLoS Genet. 2010 Oct 14;6(10):e1001157
pubmed: 20976248
Front Immunol. 2018 Oct 30;9:2463
pubmed: 30425713
Hum Immunol. 2014 Jun;75(6):570-7
pubmed: 24530754
Am J Ophthalmol. 1992 Jan 15;113(1):33-5
pubmed: 1728143
J Immunol. 2019 Sep 15;203(6):1629-1635
pubmed: 31405953
Mol Immunol. 2020 May;121:7-19
pubmed: 32135401
Ann Rheum Dis. 2016 Dec;75(12):2208-2211
pubmed: 27217550
Am J Ophthalmol. 2021 Aug;228:65-71
pubmed: 33845003
Eye (Lond). 2012 Jun;26(6):862-5
pubmed: 22402699
Nat Commun. 2019 Nov 28;10(1):5436
pubmed: 31780650